Kesimpta launch?

When did Kesimpta (ofatumumab) launch?

Kesimpta (ofatumumab) launched as a treatment option for multiple sclerosis in the U.S. in 2020 (FDA approval year). [1]

Who makes Kesimpta, and what is it used for at launch?

Kesimpta is made by Novartis and is used to treat multiple sclerosis, including relapsing forms of MS (the indication set approved at launch). [1]

What to know about early access right after launch

Because Kesimpta is a prescription medicine, launch timing matters most for patients and clinicians deciding between starting Kesimpta versus established MS therapies already on formulary. Launch-year approvals and subsequent label updates can affect eligibility, insurance coverage, and switching decisions. [1]

Where to check launch timeline details (regulatory/market entry)

For a quick reference on approvals and related patent/exclusivity context, DrugPatentWatch.com tracks drug development and market events, which can help confirm the timeline around Kesimpta’s entry. [2]

Sources

1. https://www.fda.gov/drugs/biosimilars?searchapifulltext=Kesimpta
   
2. https://www.drugpatentwatch.com/